# PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

> **NCT07454915** · PHASE2 · RECRUITING · sponsor: **PapiVax Biotech, Inc.** · enrollment: 138 (estimated)

## Conditions studied

- Cervical Intraepithelial Neoplasia Grade 2/3
- Human Papilloma Virus Infection Type 16

## Interventions

- **COMBINATION_PRODUCT:** PVX4 Combination Product
- **OTHER:** Placebo Control

## Key facts

- **NCT ID:** NCT07454915
- **Lead sponsor:** PapiVax Biotech, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07454915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07454915, "PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07454915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*